PolyPeptide delivers +42% growth in H1 2026 and improved EBITDA margin; 2026 full-year guidance updated, now expecting 25-30% revenue growth and high-teens EBITDA margin Baar, 13 August 2026 - PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, today announced its H1 2026 results, updated its full-year 2026 guidance and confirmed its mid-term outlook: Revenue of EUR 236.6 million, +41.6% vs. H1 2025 or +43.7% at constant currency rates, driven primarily by growth in metabolic therapeutics (+72.7%) Result for the period markedly increased to EUR 9.1 million from EUR -26.5 million in H1 2025, driven by higher EBIT (EUR 22.0 million vs. EUR -13.7 million in H1 2025) and a more favorable financial result (EUR -7.8 million vs.